Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Vacancies
PRIORITIES
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
SUSTAINABILITY
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Publications
By group
By type
External Resources
Factsheets
Infographics
PODCAST
Policy
Reports
Videos
Newsroom
Twitter
Tweets
Videos
Photos
Factsheet: About the Value Added Medicines Group
2 November 2026
Factsheet
Read More
White Paper: Tailoring Healthcare for Europe: The Strategy of Investing in Value Added Medicines
2 November 2026
Policy
Read More
EU Public Procurement – Communications & Policy Toolkit
21 October 2026
Policy
Read More
Memo on Cardiovascular Diseases Management
19 October 2026
Policy
Read More
Position paper on the Biotech Act
19 October 2026
Policy
Read More
Open letter on Strengthening Ukraine’s Pharmaceutical Regulatory System through the Establishment of the New National Competent Authority
16 October 2026
Policy
Read More
Medicines for Europe’s comment on the CJEU Referral on the Export Exemption (Case C-371/26)
23 July 2026
Policy
Read More
MEMO on a competitiveness strategy for the European healthcare sector
10 June 2026
Policy
Read More
Review of the SPC Manufacturing Waiver: a 2026 Industry Report
9 June 2026
Report
Read More
Recommendations to National Authorities on the Use of External Reference Pricing (ERP)
27 May 2026
Factsheet, Policy
Read More
Posts navigation
1
2
3
…
33
Subscribe to our newsletter
[contact-form-7 id="1638" title="Newsletter subscription"]
Medicines For Europe
Who we are
Vacancies
PRIORITIES
Key topics – COVID-19
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Search
Share This
LinkedIn
Share on Mastodon
Enter your Mastodon instance URL (optional)
Share
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
